IBD Tests and Markers: What They Mean and What Doctors Look For

An IBD result can arrive as a number, a coloured flag or a sentence in a report. It is tempting to read it as a verdict: normal means well, high means a flare, lower means the treatment is working.

Most results are not verdicts. They are clues answering different questions. A doctor usually reads them beside your symptoms, your usual baseline, previous results, medicines and your general health.

The useful question is not only Is this result normal? It is What was this test looking for, and what happens next?

Mirae can keep available results beside symptoms, medicines and changes in daily life. This context can help you prepare a clearer question for your care team, but Mirae does not interpret the result or decide what it means.

Start with the question, not the number

IBD tests commonly help the care team answer:

One test may contribute to more than one question, but no single marker describes the whole disease. Guidance for ulcerative colitis and guidance for Crohn's disease both recommend using symptoms and biomarkers together rather than relying on symptoms alone.

Fecal calprotectin: a clue from the bowel

Fecal calprotectin is a non-invasive marker of inflammation in the bowel. It measures a protein released by certain white blood cells and is often more closely connected to intestinal inflammation than a general blood marker.

A raised result does not prove that IBD is active. Infection, other bowel inflammation and some medicines can also affect it. A low result can be reassuring in the right setting, but it does not rule out every cause of symptoms or every form and location of Crohn's disease.

There is no single cut-off for every situation. Hospitals and laboratories may use different ranges, and a value used during diagnosis may not be the target used for monitoring. Read the result against your own report and previous comparable tests.

CRP: a broader sign of inflammation

C-reactive protein (CRP) is made by the liver and can rise when there is inflammation anywhere in the body. Infection and conditions unrelated to IBD can raise it too. Erythrocyte sedimentation rate (ESR) is another general blood marker that may be checked alongside CRP.

Not everyone with active IBD has a large rise in CRP. A normal result does not override symptoms, calprotectin, colonoscopy or imaging. Your own pattern may be more useful: did CRP rise during a confirmed flare, and fall as inflammation settled?

One high result rarely answers the question on its own. The trend, size of the change and what was happening at the time matter more than the flag.

Blood tests show more than inflammation

A full blood count does not measure bowel inflammation directly. It can show anaemia (anemia) or changes in white blood cells and platelets that need other results to explain.

• Haemoglobin, red-cell size and iron studies help assess anaemia and how much iron is available. Inflammation can raise ferritin, so it is interpreted alongside other markers.
• Albumin can fall with inflammation, reduced intake or protein loss. A low result is not a nutrition score on its own.
• Vitamin B12, folate and vitamin D may be checked when disease location, surgery, diet or treatment makes a deficiency more likely.
• Kidney, liver and electrolyte results can show dehydration, another health problem or a treatment effect.

One blood draw can therefore contribute to several questions: is there inflammation, is treatment safe, and has illness affected blood counts or nutrition? Not every abnormal flag measures the flare.

Stool tests check whether infection could explain the change

An infection can cause the same diarrhoea, urgency, pain or bleeding as an IBD flare. Stool culture or molecular tests can look for organisms such as Clostridioides difficile (C. diff). Recent illness, travel or antibiotic use can help the team decide what to test for.

Calprotectin can show that inflammation may be present, but not what caused it. British Society of Gastroenterology guidance recommends testing for infection when new or worsening IBD symptoms could represent a flare because the next step may be different.

Colonoscopy and imaging show what markers cannot

A colonoscopy gives the clinician a direct view of the bowel lining. It can show active inflammation, healing and visible changes such as narrowing, bleeding or polyps. Small tissue samples, called biopsies, are often taken during the procedure to look for microscopic inflammation and cell changes.

It may help establish a diagnosis, explain a mismatch between symptoms and markers, check response to treatment or look for precancerous change during IBD bowel cancer surveillance. The NHS overview of ulcerative colitis testing explains how a colonoscopy can contribute information that blood and stool tests cannot provide.

A colonoscopy cannot see every part of the small bowel or beyond its inner surface. Some people with Crohn's disease may therefore need another type of scope, MRI, CT, intestinal ultrasound or capsule endoscopy. Each answers a different question, so a second test does not mean the colonoscopy failed.

Medicine levels answer a different question

For some biologic medicines, a blood test may measure the medicine just before the next dose and check for antibodies. This shows exposure to that treatment; it does not show whether the bowel has healed.

The result is read beside dose timing, symptoms, objective inflammation and the reason for testing. Medicine-level testing is not used for every IBD treatment. Do not move or repeat a dose unless your prescribing team changes the plan.

What your doctor is trying to piece together

Your doctor is not looking for one perfect number. They are checking whether the different pieces tell a coherent story:

• Are symptoms and objective inflammation moving together?
• Is the current treatment controlling inflammation without causing harm?
• Is there anaemia, deficiency, infection, dehydration or a complication?
• Has IBD changed where or how it affects the bowel or daily life?
• Is more certainty needed before keeping or changing the plan?

A mismatch is useful information in itself. Symptoms can remain difficult when inflammation markers are low, and inflammation can be present while symptoms are quiet. Either situation needs a question, not a guess.

Keep each result with its context

Use Mirae to keep available laboratory results beside symptoms, medicines, changes in daily life and the questions you want to ask. It brings the clinical result and your lived experience into one timeline; it does not interpret the result.

Keep only the details that help you compare it or ask what happens next:

Test and sample type:
Date collected:
Result, unit and laboratory range:
Previous comparable result and date:

Symptoms and daily-life changes at the time:
Medicines, recent infection or dose changes:

Why the test was ordered:
What I was told it means:
Next action, who is responsible and when:
My remaining question:

When preparing for an IBD appointment, Mirae can help turn the relevant entries into a summary in the app or on the web. Bring the trend and the unresolved question rather than screenshots of every result:

My calprotectin was higher than my previous two results, but my symptoms have changed only slightly. What might explain the mismatch, and do we need to repeat or confirm anything before changing the plan?

If symptoms are severe or worsening quickly, seek medical help rather than waiting for a marker or trying to interpret one. The guide to managing a possible IBD flare covers when recording should stop and urgent care should begin.

Medical and product note

This guide provides general information for adults living with IBD. Test methods, reference ranges, surveillance schedules and clinical decisions vary by person and service. A result should be interpreted by the clinician who knows why it was requested.

Mirae can organise results and context, but it does not diagnose, interpret tests or recommend treatment changes, and its AI can be incomplete or wrong.

References

1. Gordon W. Moran et al. British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. Gut, 2025.
2. Siddharth Singh et al. The role of biomarkers for the management of ulcerative colitis. American Gastroenterological Association, 2023.
3. Ashwin N. Ananthakrishnan et al. The role of biomarkers for the management of Crohn's disease. American Gastroenterological Association, 2023.
4. National Health Service. Ulcerative colitis. NHS, reviewed 2026.